Why You Should Invest In Psychedelic Stocks

 Psychedelic stocks are on the rise, and the timing couldn’t be better. While some of these companies are already publicly traded, many of them will have their initial public offerings (IPOs) in 2022, creating new opportunities for those who want to capitalize on the growing popularity of psilocybin mushrooms and LSD as health supplements and recreational drugs alike.

What Are Psychedelics?

 

The term psychedelic was coined by British psychiatrist Humphry Osmond and stems from two Greek words that mean mind-manifesting. Psychedelics can produce profound changes in perception, thoughts, feelings, and a sense of expanded spiritual awareness. Common psychedelics include LSD (lysergic acid diethylamide), DMT (dimethyltryptamine), and psilocybin—but there are more than 200 others.

As evidenced by clinical trials with psilocybin, these drugs have medicinal uses; in fact, research suggests they may also help with depression and addiction. Scientists think serotonin and other neurotransmitters might play an important role in their effects on brain activity. LSD is being studied as an experimental treatment for anxiety linked to terminal illness and cancer treatment-related symptoms, such as anxiety about death itself. There’s also some evidence that psychedelics could be used to help people with post-traumatic stress disorder.

Psychedelic Science Gains Momentum

The Food and Drug Administration (FDA) recently lifted a long-standing ban on psychedelic drugs, opening up research opportunities for scientists to examine their therapeutic potential. The move represents an important turning point for medical professionals and patients alike. Psychedelic drugs have been linked to several benefits, including reducing anxiety, depression, and addiction.

Five Companies That Could Take Off

Here are five companies with already established support for psychedelics that could see their market values soar within a few years. This is not financial advice, but given how well these companies have been positioned over the past decade, it’s hard to deny they will be good investment choices within a few years of legalization.
 
 1) GW Pharmaceuticals: This company is using cannabis as a treatment for patients with epilepsy and other conditions. Their stock has done very well since its IPO; however, if legalization takes off, then we could see exponential growth based on projected market share in specific states and countries.

2) Amazon (NASDAQ: AMZN): Last year was a tough one for Amazon shareholders; however, I think things are going to start looking up soon thanks to Jeff Bezos putting his interests back into play.

Field Trip Health Stock

This Toronto-based start-up (launched in 2019) approaches psychedelics in a somewhat different way. The firm provides psychedelic-assisted psychotherapy, in which a licensed clinician administers the drug and accompanies you through the experience. They can assist you in your psychedelic quest. It's regarded as a complementary treatment for depression, anxiety, and trauma.

Bright Minds Biosciences Stock

Bright Minds Biosciences, Inc. is a Canada-based biotechnology company that specializes in the creation of serotonergic medicines for the treatment of mental illnesses. Its diverse array of novel chemical entities is designed to treat a wide range of pain, epilepsy, and neuropsychiatric diseases. As a result, it's a psychedelic stock that promises a lot more than the prospect of a single chemical class becoming mainstream.

COMPASS Pathways PLC Stock

Compass Pathways is dedicated to psilocybin treatment, a type of psychedelic-assisted psychotherapy that can be used to treat a variety of mental health concerns. The FDA has given the corporation permission to research psychedelics and their impact on therapy.